Electroacupuncture restores intestinal mucosal barrier in IBS-D rats by modulating mast cell-derived exosomal MiR-149-5p.

Researchers investigated how electroacupuncture might help people with diarrhea-predominant irritable bowel syndrome (IBS-D), a condition causing chronic abdominal pain and frequent diarrhea. The study used rats that were given IBS-D symptoms through stress and laxative administration, then treated with electroacupuncture. The scientists discovered that electroacupuncture works by affecting the intestinal barrier—the protective lining of the gut that prevents harmful substances from entering the bloodstream. In IBS-D, this barrier becomes damaged, leading to symptoms. The research found that electroacupuncture helps repair this barrier by reducing the activation of mast cells, which are immune cells that release inflammatory substances. Specifically, the treatment decreased levels of certain molecules called microRNAs (particularly miR-149-5p) that are carried in tiny packages called exosomes released by mast cells. These microRNAs normally damage the tight junctions between intestinal cells, making the barrier leaky. By lowering these harmful microRNAs, electroacupuncture strengthened the intestinal barrier and improved IBS-D symptoms including pain sensitivity and diarrhea frequency. The study also showed that electroacupuncture reduced stress-related chemical signals (CRF and CRF-R1) that trigger mast cell activation. This research provides scientific evidence for how electroacupuncture may benefit IBS-D patients at the cellular and molecular level, suggesting it could be a valuable treatment option for strengthening gut health and reducing symptoms. If you're considering acupuncture for digestive issues, seek treatment from a licensed acupuncturist with experience in gastrointestinal conditions.

This study investigated electroacupuncture's mechanism in treating IBS-D through mast cell-derived exosomal microRNA modulation. Rats underwent chronic unpredictable mild stress plus Senna administration to induce IBS-D, confirmed via visceral pain threshold, diarrhea index, and histopathology. EA treatment downregulated CRF/CRF-R1 expression, inhibited mast cell degranulation, and upregulated tight junction proteins (assessed via qPCR, TEM, IHC, Western blot, and ELISA). These therapeutic effects were abolished by mast cell agonist C48/80 and CRF-R1 agonist Ucn1, but enhanced by exosome inhibitor GW4869. MiRNA sequencing revealed significantly elevated miR-149-5p and miR-22-5p in MC-EXO from model rats versus EA-treated animals. In vitro transfection of Caco-2 cells with these miRNA mimics increased monolayer permeability and decreased tight junction expression. AAV-mediated miR-149-5p overexpression negated EA's protective effects. Clinical takeaway: EA appears to restore intestinal barrier integrity in IBS-D by suppressing mast cell-derived exosomal miR-149-5p, providing mechanistic support for EA in treating stress-related IBS-D with barrier dysfunction.